Treatments for TNBC have historically been confined to surgery, radiation and chemotherapies due to the lack of biologic targets which enable endocrine therapy (ER and PR) and targeted therapy (HER2) in other subgroups of breast cancer. This evidence concerns the gene PGR and breast carcinoma.